Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...

A new analysis of 11 global studies shows that people tend to regain lost weight after stopping anti-obesity medications like ...

A WOMAN who shed a whopping 6st in just nine months has shared the secret behind not pilling back all the pounds when eating out. Lucy Davies kickstarted her weight loss journey with the popular ...

Sally Love has always enjoyed a drink - but, like many, it was during the Covid pandemic that her alcohol intake began to ...

"We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria. "DehydraTECH is continuing to demonstrate ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...